Aptahem plans for a rights issue of SEK 9.7 million

Swedish biotech company Aptahem has announced a rights issue of approximately SEK 9.

7 million aimed at financing the continued clinical development of its lead drug candidate, Apta-1. The therapeutic candidate is being developed for the treatment of life-threatening inflammatory conditions, including sepsis.